Construction of a prognostic model based on efferocytosis for predicting survival and immunotherapy efficacy in cervical cancer

This systematic analysis of ERGs led to the development of a prognostic risk model incorporating <i>EPO</i> and <i>UCP2</i> for patients with CC. For the specific cohort of HPV16-positive, early-stage (IA-IIA) patients, this tool has potential clinical utility in identifying high-risk individuals who may benefit from intensified post-operative management or immunotherapy.